A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα-positive solid tumours: Results in the endometrial cancer (EC) cohort

被引：2
|
作者：
Cristea, M. C. [1 ]
Frankel, P. [2 ]
Synold, T. [3 ]
Stewart, D. B. [1 ]
Wang, E. [1 ]
Jung, A. [4 ]
Wilczynski, S. [5 ]
Tran, M. [5 ]
Konecny, G. E. [6 ]
Eng, M. [7 ]
Kilpatrick, L. [8 ]
Chen, Y-J. [9 ]
Glaser, S. [9 ]
Han, E. [10 ]
Dellinger, T. [10 ]
Hakim, A. [10 ]
Lee, S. [10 ]
Morgan, R. J. [1 ]
Rodriguez, L. [10 ]
Wakabayashi, M. [10 ]
机构：
[1] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[2] City Hope Comprehens Canc Ctr, Dept Computat & Quantitat Med, Duarte, CA USA
[3] City Hope Natl Med Ctr, Canc Biol, Duarte, CA USA
[4] City Hope Comprehens Canc Ctr, Diagnost Radiol, Duarte, CA USA
[5] City Hope Comprehens Canc Ctr, Div Program, Duarte, CA USA
[6] Univ Calif Los Angeles, Dept Med, David Geffen Sch, Los Angeles, CA 90024 USA
[7] City Hope Natl Med Ctr, Div Program, Duarte, CA USA
[8] City Hope Natl Med Ctr, Shared Rsc Clin Trial Off, Duarte, CA USA
[9] City Hope Comprehens Canc Ctr, Radiat Oncol, Duarte, CA USA
[10] City Hope Comprehens Canc Ctr, Surg, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
863P
引用
收藏
页码：S639 / S639
页数：1
相关论文
共 50 条
  • [41] CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    de Braud, F.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S464 - S464
  • [42] FINAL RESULTS OF THE PHASE I COMPONENT OF A PHASE I/IIA STUDY OF CHEMOTHERAPY WITH BENDAMUSTINE AND IRINOTECAN (BI) FOLLOWED BY ETOPOSIDE/CARBOPLATIN (EC) IN UNTREATED PATIENTS (PTS) WITH EXTENSIVE SMALL CELL LUNG CANCER (E-SCLC)
    Bordoni, Rodolfo E.
    Robert, Francisco
    Saleh, Mansoor
    Dixon, Pam
    Howell, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S142 - S142
  • [43] Phase (Ph) I/II study of pembrolizumab (P) with gemcitabine (G) in patients (pts) with previously-treated advanced (Adv) non-small cell lung cancer (NSCLC).
    Sanborn, Rachel E.
    Duffy, Regan M.
    Fisher, Brenda K.
    Perlewitz, Kelly Shea
    Wallen, Herschel D.
    Li, Rui
    Redmond, William L.
    Koguchi, Yoshinobu
    Fox, Bernard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)
    Evans, T.
    Ramanathan, R. K.
    Yazji, S.
    Glynne-Jones, R.
    Anthoney, A.
    Berlin, J.
    Valle, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Phase (Ph) I/Ib trial of fruquintinib (fru) in patients (pts) with advanced solid tumors: Preliminary results of the dose expansion (exp) cohort in refractory metastatic colorectal cancer (mCRC)
    Dasari, N. A.
    Wang-Gillam, A.
    Hubbard, J. M.
    Fernandez, A.
    Nanda, S.
    Kania, M.
    Schelman, W. R.
    Bekaii-Saab, T. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S436 - S437
  • [46] Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
    O'Malley, David M.
    Moore, Kathleen N.
    Vergote, Ignace
    Martin, Lainie P.
    Gilbert, Lucy
    Martin, Antonio Gonzalez
    Nepert, Dale L.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors
    Garralda, E.
    Fiedler, W.
    Matos, I.
    Rolling, C.
    Kebenko, M.
    Klinghammer, K.
    Conte, G.
    Raspagliesi, F.
    Habel, B.
    Baumeister, H.
    Ochsenreither, S.
    Zurlo, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 125 - 125
  • [48] Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
    Eads, J.
    Stein, S.
    El-Khoueiry, A.
    Manji, G.
    Abrams, T.
    Khorana, A. A.
    Miksad, R.
    Mahalingam, D.
    Sirard, C.
    Zhu, A. X.
    Goyal, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Preliminary results of the phase I and pharmacokinetic study.
    Lemarie, E
    Bennouna, J
    Grossi, F
    Pinel, MC
    Sennellart, H
    Longerey, B
    Douillard, JY
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 686S - 686S
  • [50] A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)
    Kozloff, M. F.
    Martin, L. P.
    Krzakowski, M.
    Samuel, T. A.
    Tarazi, J.
    Rosbrook, B.
    Tortorici, M.
    Olszanski, A. J.
    Cohen, R. B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 130 - 130
12345